Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Maryland, Baltimore

Criteria

Inclusion Criteria:

1. Age greater than 40 and less than 80 years

2. Clinical suspicion or history of prostate cancer reflected by one of the following:

• PSA > 4ng/ml

• Abnormal DRE exam

• Known tissue diagnosis of prostate cancer from prior workup

3. Patient planning to undergo either a MRI targeted biopsy or radical prostatectomy for prostate cancer workup or treatment

Exclusion Criteria:

1. Inability to undergo MRI scan

2. Inability to receive IV contrast as per institutional protocol.